Chemotherapy

Chemotherapy related articles.

January 19, 2024
Published by TDP on January 19, 2024
Categories

Why Atezolizumab and Chemotherapy Should Be Used with Caution in Real-World SCLC Population

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
Do you like it?33
0 Read more
June 28, 2023
Published by TDP on June 28, 2023
Categories

What are the top side effects of Ponatinib

Ponatinib is a medication that is used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) when other treatments have not been effective. Like all medications, Ponatinib has potential side effects. Here are some of the most common ones:
Do you like it?52
0 Read more
January 15, 2021
Published by TDP on January 15, 2021
Categories

3 Highlights about Ovarian Cancer: Options and Risks

This is an important thing that's our patients are worried about this. And this is something that we, as a group need to ask ourselves, how can we improve our adherence? and how to deal with ovarian cancer: options and risks
Do you like it?80
2 Read more
January 15, 2021
Published by TDP on January 15, 2021
Categories

4 Dimensions to Improve Cancer Patient Quality Of Life

Cancer care is advancing. And we have more and more clinical trials, as well as new agents that we need to always remain focused on what our treatments mean, in terms of quality of life for patients and for their families. Because for all of us, quality of life, remains the ultimate goal of all of our cancer treatments. # Cancer Patient Quality Of Life
Do you like it?25
2 Read more
1234
Simple Ways to Manage Lynparza/Olaparib-Induced Nausea Ovarian Cancer
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more